Overview
SLSBT Pharma is developing the first, non-hormonal therapy for endometriosis. The company holds exclusive rights to issued US and European patents. Following a successful Pre-IND in 2022, the company is developing an IND to open a Phase 2b dose-finding study in mid-2023. Upon approval, this will be the first therapy for endometriosis that allows a woman to treat her disease and achieve pregnancy.